<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lynch EM</submitter><funding>HHS | NIH | NIH Office of the Director</funding><funding>HHS | NIH | National Institute of General Medical Sciences</funding><funding>NIAID NIH HHS</funding><funding>HHS | NIH | National Institute of Allergy and Infectious Diseases</funding><funding>NIGMS NIH HHS</funding><funding>NIH HHS</funding><pagination>e2107968118</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8501788</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>118(40)</volume><pubmed_abstract>Cytidine triphosphate synthase 1 (CTPS1) is necessary for an effective immune response, as revealed by severe immunodeficiency in CTPS1-deficient individuals [E. Martin &lt;i>et al&lt;/i>], [&lt;i>Nature&lt;/i>] [510], [288-292] ([2014]). CTPS1 expression is up-regulated in activated lymphocytes to expand CTP pools [E. Martin &lt;i>et al&lt;/i>], [&lt;i>Nature&lt;/i>] [510], [288-292] ([2014]), satisfying increased demand for nucleic acid and lipid synthesis [L. D. Fairbanks, M. Bofill, K. Ruckemann, H. A. Simmonds], [&lt;i>J. Biol. Chem.&lt;/i> ] [270], [29682-29689] ([1995]). Demand for CTP in other tissues is met by the CTPS2 isoform and nucleoside salvage pathways [E. Martin &lt;i>et al&lt;/i>], [&lt;i>Nature&lt;/i>] [510], [288-292] ([2014]). Selective inhibition of the proliferative CTPS1 isoform is therefore desirable in th</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>Structural basis for isoform-specific inhibition of human CTPS1.</pubmed_title><pmcid>PMC8501788</pmcid><funding_grant_id>GM007270</funding_grant_id><funding_grant_id>R01 AI153048</funding_grant_id><funding_grant_id>S10 OD023476</funding_grant_id><funding_grant_id>GM118396</funding_grant_id><funding_grant_id>R01 GM118396</funding_grant_id><funding_grant_id>S10OD032290</funding_grant_id><funding_grant_id>AI153048</funding_grant_id><funding_grant_id>T32 GM007270</funding_grant_id><pubmed_authors>Lynch EM</pubmed_authors><pubmed_authors>Hansen JM</pubmed_authors><pubmed_authors>Quispe JD</pubmed_authors><pubmed_authors>Kaila N</pubmed_authors><pubmed_authors>Albanese S</pubmed_authors><pubmed_authors>McElwee JJ</pubmed_authors><pubmed_authors>Kennedy MA</pubmed_authors><pubmed_authors>Kreutter KD</pubmed_authors><pubmed_authors>Kollman JM</pubmed_authors><pubmed_authors>Verras A</pubmed_authors><pubmed_authors>Borrelli K</pubmed_authors><pubmed_authors>DiMattia MA</pubmed_authors><pubmed_authors>Toms AV</pubmed_authors><pubmed_authors>van Zundert GCP</pubmed_authors></additional><is_claimable>false</is_claimable><name>Structural basis for isoform-specific inhibition of human CTPS1.</name><description>Cytidine triphosphate synthase 1 (CTPS1) is necessary for an effective immune response, as revealed by severe immunodeficiency in CTPS1-deficient individuals [E. Martin &lt;i>et al&lt;/i>], [&lt;i>Nature&lt;/i>] [510], [288-292] ([2014]). CTPS1 expression is up-regulated in activated lymphocytes to expand CTP pools [E. Martin &lt;i>et al&lt;/i>], [&lt;i>Nature&lt;/i>] [510], [288-292] ([2014]), satisfying increased demand for nucleic acid and lipid synthesis [L. D. Fairbanks, M. Bofill, K. Ruckemann, H. A. Simmonds], [&lt;i>J. Biol. Chem.&lt;/i> ] [270], [29682-29689] ([1995]). Demand for CTP in other tissues is met by the CTPS2 isoform and nucleoside salvage pathways [E. Martin &lt;i>et al&lt;/i>], [&lt;i>Nature&lt;/i>] [510], [288-292] ([2014]). Selective inhibition of the proliferative CTPS1 isoform is therefore desirable in th</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Oct</publication><modification>2026-06-12T08:59:44.492Z</modification><creation>2025-02-19T00:03:22.107Z</creation></dates><accession>S-EPMC8501788</accession><cross_references><pubmed>34583994</pubmed><doi>10.1073/pnas.2107968118</doi></cross_references></HashMap>